You are here
From patented antibodies to tumour associated cell surface markers. We have a diverse portfolio with the opportunity to licence agents in pre-clinical to Phase II clinical development.
This opportunity has produced a lead T-Cell Receptor mimic (TCRm) monoclonal antibody (mAb) against an HLA-A*0201 presented peptide derived from the cancer target p53, that is mutated in 50% of humRead more
A summary of all of our antibody and peptide opportunities can be found in the presentation linked below.Read more
We are seeking a commercial partner for licensing and/or collaborative development of potential best-in-class therapeutic anti-CCR4 antibodies.Read more
The anti-TACE antibody comes with an extensive package of data demonstrating high affinity binding, potent inhibitory action against TACE in vitro and in vivo, a long in vivo halflife and in vivo eRead more